Modalis Therapeutics Corporation
Code | Sector | Market |
---|---|---|
4883 | Pharmaceuticals | MTH |
Date of listing approval | 2020/06/26 |
---|---|
Expected Date | 2020/08/03 |
Lead Underwriter | Mizuho |
Description | Research and development of gene therapy drugs using the core platform technology "Incisive CRISPR technology (CRISPR-GNDM technology)" |
Listed Shares(total) | 3,105,000 |
---|---|
Trading Unit | 100 |
New Shares | 2,100,000 |
Existing Shares | 1,005,000¡Êincl. O.A.¡Ë |
Shares Outstanding | PreIPO 25,100,000.00 |
PostIPO 27,200,000.00 | |
Paid Up Capital | PreIPO Y1,300,000,000 |
PostIPO Y2,075,008,000 | |
Expected Pricing Date | 2020/07/10 |
Book Building Start | 2020/07/14 |
Book Building End | 2020/07/20 |
Fix Date | 2020/07/21 |
Offering Starts | 2020/07/22 |
Offering Ends | 2020/07/29 |
Expect Pricing | Y1,000-Y1,200 |
Notional PER (based on previous period) |
167.79-201.34 |
Offering Price | Y1,200 |
Offering Price PER (based on previous period) |
- |
Offering Price PBR (based on previous period) |
7.84 |
Use of Funds Raised |
Financial Data
Units:Y1,000
Fiscal Year End:2017/12 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | 17,921 |
Current Profit | - | -141,200 |
Net Profit | - | -142,150 |
Net Assets | - | 1,421,735 |
Fiscal Year End:2018/12 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | 65,297 | 65,297 |
Current Profit | -213,390 | -228,981 |
Net Profit | -217,909 | -229,932 |
Net Assets | 1,201,779 | 1,191,802 |
Fiscal Year End:2019/12 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | 644,500 | 644,500 |
Current Profit | 146,351 | 128,822 |
Net Profit | 140,528 | 127,899 |
Net Assets | 3,842,542 | 3,819,701 |
Recent Quarter 2020/03 |
||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | 13,000 | - |
Current Profit | -116,924 | - |
Net Profit | -118,286 | - |
Net Assets | 3,724,455 | - |
Per Share Units:Y1
Fiscal Year End:2017/12 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | - |
Equity | -10.29 | -3.89 |
Fiscal Year End:2018/12 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | -10.84 | -14.84 |
Equity | -11.44 | -15.33 |
Fiscal Year End:2019/12 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | 5.96 | 153.09 |
Equity | 5.43 | 152.18 |
Fiscal Year End:Recent Quarter 2020/03 |
||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | ||
Net Earning | -4.71 | - |
Equity | - | - |
Comment
¢£Over allotment(405,000) |
Consolidated Subsidiaries
Name | Address |
---|
Underwriters
Allocation | Underwriter | Tel |
---|---|---|
0% | Nomura | 03-3211-1811 |
75% | Mizuho | 03-5208-3210 |
11% | SBI SECURITIES Co.,Ltd. | 03-5562-7210 |
11% | SMBC Nikko | 03-5644-3111 |
1.5% | Ichiyoshi | 03-3555-6210 |
1.5% | Ace | 06-6267-2111 |
Data
Date of incorporation | 2016/01/14 |
---|---|
Company address | Tokyo 103-0026 |
Telephone | 03-6822-4584 |
President | |
Homepage | https://www.modalistx.com/jp/ |
Auditor | Azsa |
Major Shareholders | |
---|---|
Shareholder Name | Ratio |
86.62% | |
17.86% | |
16.07% | |
8.39% | |
8.39% | |
3.75% | |
3.57% | |
2.86% | |
2.68% | |
2.68% | |
2.59% |
Number of Employees | 3 as of 2020/05/31 |
---|---|
Birth Date of Representative | 1969/08/09 |